Naturkosmetik und die Attitude-Behavior-Gap: – Umweltwissen, (Hersteller-)Transparenz und soziale Normen machen bei jungen Erwachsenen den entscheidenden Unterschied.

Autor: Wons, K.¹, Bendig, M.² mirko.bendig@iu.org

Publikováno v: SOFW Journal (German version). Jan2023, Vol. 149 Issue 1/2, p32-38. 7p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies.

Autor: Dippel A; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Gallegos A; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Aleti V; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Barnes A; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Chen X; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA., Christian E; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Delmar J; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Du Q; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Esfandiary R; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Farmer E; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Garcia A; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Li Q; Hansoh Bio, Rockville, MD, USA.; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Lin J; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Liu W; Pfizer, La Jolla, CA, USA.; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA., Machiesky L; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Mody N; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Parupudi A; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Prophet M; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Rickert K; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Rosenthal K; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Ren S; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA., Shandilya H; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Varkey R; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Wons K; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Wu Y; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA., Loo YM; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Esser MT; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Kallewaard NL; Eli Lilly, Indianapolis, IN, USA.; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Rajan S; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Damschroder M; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA., Xu W; Biopharmaceutical Development, MacroGenics, Rockville, MD, USA.; Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA., Kaplan G; Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Publikováno v: MAbs [MAbs] 2023 Jan-Dec; Vol. 15 (1), pp. 2152526.